Part of our complete guide to eczema and dermatitis in the UK.
How Does Dermovate Work? Clobetasol Propionate Explained
A clinical guide to Dermovate (clobetasol propionate 0.05%) — UK Class 4 very potent topical steroid. Covers mechanism of action, MHRA prescribing limits, full side-effect profile, and the step-up/step-down steroid ladder.
▶ What is Dermovate?
Dermovate contains clobetasol propionate 0.05% — a very potent (UK Class 4) topical corticosteroid, the highest potency class available. It works by binding to glucocorticoid receptors in skin cells, suppressing the inflammatory cytokines, prostaglandins, and immune signals that drive severe eczema, psoriasis, and other resistant dermatoses. It is reserved for short courses where Class 3 steroids (Betnovate) have been insufficient. Maximum 50g per week. GPhC pharmacy #9011198.
Dermovate is one of the most clinically powerful topical treatments available in UK dermatology. Understanding how it works — and why its classification matters — is essential for anyone being prescribed it or considering it for a skin condition that has not responded to less potent treatments.
Get Dermovate Online via Access Doctor
GPhC-registered pharmacist independent prescribers. Dermovate cream, ointment and scalp lotion available following clinical assessment. Discreet next-day delivery. GPhC pharmacy #9011198.
Start Consultation →What Is Clobetasol Propionate?
Clobetasol propionate is a synthetic fluorinated glucocorticosteroid — a man-made form of the steroid hormones naturally produced by the adrenal glands. At 0.05% concentration, it is the active ingredient in Dermovate cream, ointment, and scalp lotion. It was developed specifically to achieve maximal topical anti-inflammatory potency at low concentrations.
In the UK, topical corticosteroids are classified into four potency groups by the British National Formulary (BNF):
| UK Class | Potency | Examples | Typical use |
|---|---|---|---|
| Class 1 | Mild | Hydrocortisone 0.5–1% | Face, mild eczema, children |
| Class 2 | Moderate | Eumovate (clobetasone 0.05%) | Moderate eczema, face with caution |
| Class 3 | Potent | Betnovate (betamethasone 0.1%), Elocon, Cutivate | Moderate-to-severe eczema on body |
| Class 4 | Very potent | Dermovate (clobetasol 0.05%) | Severe, resistant, or lichenified skin only; short courses |
Dermovate is approximately 600 times more potent than hydrocortisone 1% on a weight-for-weight basis. This extraordinary potency is why it works when other steroids have failed — and why its use must be carefully limited. For formulation-specific guidance, see: Dermovate cream for eczema and Dermovate ointment for dry skin.
How Dermovate Works: The Mechanism
Clobetasol propionate acts through the glucocorticoid receptor (GR), a nuclear receptor found in virtually all cell types. When applied topically, the molecule penetrates the skin and binds to GRs inside immune and inflammatory cells. This triggers a cascade of anti-inflammatory effects:
Cytokine suppression
Blocks production of pro-inflammatory cytokines including IL-1, IL-2, IL-6, TNF-α and interferon-γ — reducing the immune signalling that drives visible inflammation.
Prostaglandin inhibition
Upregulates lipocortin, which inhibits phospholipase A2 — the enzyme that generates arachidonic acid and downstream prostaglandins and leukotrienes responsible for pain, swelling and redness.
Vasoconstriction
Causes local vasoconstriction, reducing the dilation of skin capillaries that produces the redness and warmth of inflammatory skin conditions. Vasoconstriction assays are used to measure relative topical corticosteroid potency.
Keratinocyte modulation
Normalises abnormal keratinocyte proliferation in hyperkeratotic conditions (psoriasis, lichenified eczema), reducing skin thickening and scaling.
The result is rapid, potent reduction in redness, swelling, itching, and scaling — typically within 24–48 hours of the first application in responsive conditions.
What Dermovate Is Used For
MHRA-licensed indications for clobetasol propionate include:
- Severe atopic eczema — where Class 3 steroids (Betnovate) have not achieved adequate control of an acute flare
- Plaque psoriasis — on the body; not for facial or flexural psoriasis
- Lichen planus — chronic inflammatory condition causing purple itchy patches
- Discoid lupus erythematosus (DLE) — short-term symptom management
- Severe contact dermatitis — where causative exposure has been removed and rapid symptom control is needed
- Lichen simplex chronicus — chronic lichenified skin secondary to repeated scratching
Dermovate is NOT appropriate for: acne, rosacea, skin infections (bacterial, fungal, viral), perioral dermatitis, or nappy rash. It must not be used on the face, eyelids, skin folds, or genitals without specialist direction. Using it in these situations risks serious side effects including perioral dermatitis and steroid-induced rosacea.
MHRA Safety Limits and Prescribing Rules
Because of its very high potency, MHRA guidance and the BNF specify strict limits for Dermovate use:
- Maximum 50g (or 50ml) per week — across all Dermovate applications combined. Exceeding this significantly raises the risk of systemic absorption and HPA axis suppression.
- Short courses — typically 1–2 weeks. If no improvement within 1 week of starting, the prescriber should be contacted to review the diagnosis.
- Not for continuous use — rest periods are required between courses. Prolonged daily application leads to tachyphylaxis (reduced effectiveness) and cumulative atrophy risk.
- Avoid occlusion — do not apply under tight bandages or dressings unless specifically prescribed, as occlusion dramatically increases absorption.
- Not for children under 1 year; use with extreme caution in children under 12, with the lowest effective amount and duration.
Side Effects and Risks
Dermovate is safe when used correctly for short courses. The risks arise primarily from prolonged use, overuse, or inappropriate application to sensitive areas:
| Side effect | Risk level | Management |
|---|---|---|
| Skin atrophy (thinning) | Common with prolonged use | Use minimum effective amount; limit course duration; avoid sensitive skin areas |
| Striae (stretch marks) | Common with prolonged use on flexible skin | Avoid application to skin folds or flexures; limit duration |
| Telangiectasia (thread veins) | Common with prolonged facial use | Never apply to face routinely; facial eczema requires specialist assessment |
| Perioral dermatitis / steroid rosacea | Risk if applied to face | Strict avoidance of facial application |
| HPA axis suppression | Rare; risk increases with large areas/high doses | Do not exceed 50g/week; monitor in prolonged use |
| Skin infections | Uncommon; risk with pre-existing infection | Never apply to infected skin; assess for secondary infection during flare |
| Posterior subcapsular cataracts / glaucoma | Rare; risk with periorbital use | Never apply near eyes without specialist direction |
Stop Dermovate and seek urgent medical advice if: You develop signs of skin infection (spreading redness, warmth, pus, fever) · visual disturbances · symptoms of adrenal insufficiency (unexplained fatigue, weight loss, dizziness, low blood pressure). Call 999 in an emergency.
Dermovate vs Betnovate: When to Step Up and Step Down
Dermovate is not first-line for most eczema presentations. The standard prescribing approach follows the NICE-recommended step-up model:
1
Start with emollients and mild steroids
For most eczema: daily emollients plus hydrocortisone 1% (Class 1) for mild flares. This should be the default for face, children, and widespread eczema.
2
Step up to Betnovate (Class 3) if needed
For moderate-to-severe flares on body areas: betamethasone valerate 0.1% (Betnovate) is potent and effective for most eczema not controlled by mild steroids. See: Betnovate UK guide.
3
Use Dermovate (Class 4) for resistant cases
For severe or lichenified skin that has not responded to Betnovate: a short course of clobetasol propionate 0.05%. Usually 1–2 weeks only. Always with prescriber supervision and a clear plan for stepping down.
4
Step back down after the flare
After a Dermovate course, step down to a lower-potency steroid or switch back to emollient-only maintenance. Do not continue Dermovate beyond the prescribed course. For cream vs ointment decision, see: Dermovate cream or Dermovate ointment.
Get Dermovate Online — GPhC-Registered Prescribers
Dermovate cream, ointment and scalp lotion available following online clinical assessment. GPhC pharmacy #9011198. Discreet next-day delivery.
View Eczema Treatments →Frequently Asked Questions
What is Dermovate used for?
Dermovate (clobetasol propionate 0.05%) is a very potent (UK Class 4) topical corticosteroid for short-course treatment of severe, resistant, or lichenified inflammatory skin conditions — including severe eczema, plaque psoriasis, lichen planus, and discoid lupus erythematosus. It is only prescribed when milder corticosteroids have been insufficient.
How strong is Dermovate?
Dermovate is classified as very potent (Class 4) in the UK — the highest potency class available. Clobetasol propionate 0.05% is approximately 600 times more potent than hydrocortisone 1% on a weight-for-weight basis, and significantly more potent than betamethasone valerate (Betnovate, Class 3).
How long can I use Dermovate for?
MHRA guidance recommends limiting Dermovate use to the shortest course necessary. A total of no more than 50g (or 50ml for lotion) per week across all applications. Courses are typically 1–2 weeks, with rest periods before any further course. Prolonged continuous use carries significant risks of skin atrophy, HPA axis suppression and systemic effects.
Who should not use Dermovate?
Dermovate is contraindicated in: children under 1 year (use with extreme caution under 12); active skin infections (bacterial, fungal or viral); rosacea; acne vulgaris; perioral dermatitis; pregnancy (very potent steroids — use only when clearly necessary); anyone with known hypersensitivity to clobetasol propionate. It should not be applied to the face, eyelids, genitals, or skin folds without specialist direction.
What is the difference between Dermovate and Betnovate?
Dermovate contains clobetasol propionate 0.05% (Class 4, very potent). Betnovate contains betamethasone valerate 0.1% (Class 3, potent). Dermovate is significantly more potent and is reserved for cases where Betnovate has been insufficient. Both require prescription. See our full Betnovate guide for the step-down comparison.
Can Dermovate cause skin thinning?
Yes. Skin atrophy (thinning) is a well-documented risk of prolonged or excessive use of potent and very potent topical corticosteroids. Clobetasol propionate carries greater atrophy risk than lower-potency steroids. To minimise this: apply the minimum effective amount, limit courses to the shortest duration necessary, avoid sensitive areas (face, genitals, skin folds), and do not use under occlusion unless prescribed.
References
- MHRA. SPC: Dermovate cream (clobetasol propionate 0.05%). 2024. medicines.org.uk/emc
- NICE. Eczema — atopic: CKS. 2024. cks.nice.org.uk
- Hengge UR et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15.
- NHS. Clobetasol propionate (Dermovate). nhs.uk/medicines/clobetasol
- BNF. Topical corticosteroids. NICE/BNF, 2024. bnf.nice.org.uk
Medical disclaimer: Dermovate is a prescription-only medicine classified as very potent (UK Class 4). It must only be used as directed by a qualified prescriber. It must not be applied to the face, eyelids, or skin folds without specialist direction. In a medical emergency, call 999.